{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:40:49Z","timestamp":1790761249138,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grifols"},{"DOI":"10.13039\/501100004628","name":"Medimmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.survophthal.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:36:18Z","timestamp":1565980578000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Optic neuritis in the era of biomarkers"],"prefix":"10.1016","volume":"65","author":[{"given":"John J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda A.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tariq","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.survophthal.2019.08.001_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.survophthal.2019.08.001_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.survophthal.2019.08.001_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A\u00a0randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.survophthal.2019.08.001_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0161-6420(95)30839-1","article-title":"What we have learned from the optic neuritis treatment trial","volume":"102","author":"Beck","year":"1995","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.08.001_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.survophthal.2019.08.001_bib6","first-page":"787630","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult Scler Int"},{"issue":"6","key":"10.1016\/j.survophthal.2019.08.001_bib7","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis - Final optic neuritis treatment trial follow-up","volume":"65","author":"Brodsky","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.survophthal.2019.08.001_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-positive optic neuritis: Clinical characteristics, radiologic clues and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.08.001_bib9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/WNO.0000000000000779","article-title":"Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome?","volume":"39","author":"Chen","year":"2019","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J\u00a0Neuroinflammation"},{"issue":"3","key":"10.1016\/j.survophthal.2019.08.001_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis optica spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.survophthal.2019.08.001_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1-2","key":"10.1016\/j.survophthal.2019.08.001_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J\u00a0Neurol Sci"},{"issue":"12","key":"10.1016\/j.survophthal.2019.08.001_bib15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: International recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"10","key":"10.1016\/j.survophthal.2019.08.001_bib20","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2019.08.001_bib21","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.survophthal.2019.08.001_bib22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","article-title":"Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the quality standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Kaufman","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.survophthal.2019.08.001_bib23","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.survophthal.2019.08.001_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"9451","key":"10.1016\/j.survophthal.2019.08.001_bib25","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.survophthal.2019.08.001_bib26","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.08.001_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: A randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.08.001_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.08.001_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2019.08.001_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.survophthal.2019.08.001_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.08.001_bib34","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.survophthal.2019.08.001_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.20913","article-title":"How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis","volume":"60","author":"Steinman","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.survophthal.2019.08.001_bib37","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.survophthal.2019.08.001_bib38","first-page":"1","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.08.001_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2019.08.001_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.survophthal.2019.08.001_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.survophthal.2019.08.001_bib42","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625719302462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625719302462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:47:05Z","timestamp":1758541625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625719302462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0039625719302462"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.08.001","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optic neuritis in the era of biomarkers","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}